Table 4.

Proposal for reporting of mutational results in GISTs

Information required	Optional information
- confirmation of the diagnosis GIST, based on morphological and immunohistochemical findings
- indicate the type of analysed material (primary tumor, metastasis, local relapse)	- indicate date of surgery if appropriate
- in case of a primary GIST indicate the individual risk classification according to consensus classification [27]	- according to [5]
- report on molecular findings for every exon analysed; indicate mutations on DNA and protein level in a standardized description according to [30]	- indicate homo-/hemizygous mutations - indicate type of examination method (e.g. PCR and DNA sequencing)
- report on expected response to imatinib treatment based on the individual mutation type, according to recent recommendations; - KIT exon 9: better response to 800 mg daily - KIT exon 11: best response (at 400 mg daily) - PDGFRA exon 18: according to special type of mutation (D842V resistant, deletions mostly responsive)	- report on prognostic relevance of the individual mutation type for clinical behaviour, according to recent data, e.g. [28]
- give an individual suggestion for adjuvant therapy, based on the individual mutation type and according to recent consensus recommendations